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Themechanisms underlying the development of com-
plications in type 1 diabetes (T1D) are poorly under-
stood. Disease modeling of induced pluripotent stem
cells (iPSCs) frompatientswith longstandingT1D (dis-
easedurationR 50 years)with severe (Medalist +C) or
absent to mild complications (Medalist C) revealed
impaired growth, reprogramming, and differentiation
in Medalist +C. Genomics and proteomics analyses
suggested differential regulation of DNA damage
checkpoint proteins favoring protection from cellular
apoptosis in Medalist C. In silico analyses showed
altered expression patterns of DNA damage check-
point factors among theMedalist groups to be targets
of miR200, whose expression was significantly
elevated in Medalist +C serum. Notably, neurons
differentiated from Medalist +C iPSCs exhibited
enhancedsusceptibility togenotoxic stress thatwors-
ened upon miR200 overexpression. Furthermore,
knockdown of miR200 in Medalist +C fibroblasts and
iPSCs rescued checkpoint protein expression and
reducedDNAdamage.WeproposemiR200-regulated
DNA damage checkpoint pathway as a potential ther-
apeutic target for treating complications of diabetes.
INTRODUCTION
Type 1 diabetes (T1D) is associated with micro- and macro-
vascular complications (Chang-Chen et al., 2008; Forbes andCelCooper, 2013; Rask-Madsen and King, 2013; Fang et al.,
2004; Schalkwijk and Stehouwer, 2005), but themechanisms un-
derlying their development remain elusive, due in part to a lack of
suitable cellular models for molecular investigation (Calcutt et al.,
2009; Reddy and Natarajan, 2011; Reddy et al., 2012; Lacolley
et al., 2009). Diabetic complications affecting the heart and
vascular cells (cardiovascular), kidney (nephropathy), eyes (reti-
nopathy), or nerves (neuropathy) arise as a consequence of
stress-induced apoptosis, resulting in loss of the functional
cellular pool and a concomitant failure of the body’s inherent
mechanism to compensate (Brownlee, 2001, 2005). Animal
modeling of these phenotypes has met with challenges over
the years, in part due to an inability to precisely mimic the human
disease phenotype. To overcome such challenges, we derived
induced pluripotent stem cells (iPSCs) from individuals with
long-standing T1D (R50 years), termed Medalist patients
(Keenan et al., 2007; Maehr et al., 2009; Park et al., 2008; Tiscor-
nia et al., 2011), and age-matched healthy controls. The Medal-
ists were extensively phenotyped by clinical examination and as-
sessed for the presence of complications and classified as those
with severe (Medalist +C) and thosewith absent tomild (Medalist
C) complications (Keenan et al., 2007, 2010). Mass spectrom-
etry (MS)-based quantitative proteomics analyses of these
iPSCs, alongwithmicroarray gene expression profiling of the pa-
tient fibroblasts used to derive the iPSCs, implicated preserved
DNA damage checkpoint pathway function, due to suppressed
miR200 expression as a mechanism underlying protection
against diabetic complications in the Medalist C subgroup.
Consistently, we observed elevated miR200 levels in sera from
Medalist +C patients. Furthermore, overexpression of miR200
in two target cell types, namely primary human neurons and
primary endothelial cells, caused downregulation of ATM pro-
tein, increased pH2AX, and cellular apoptosis. Corroboratively,l Metabolism 22, 239–252, August 4, 2015 ª2015 Elsevier Inc. 239
Table 1. Clinical Characteristics of Longstanding T1D Patients
Used for iPSC Derivation
Group Gender Age (years)
Duration of Diabetes
(years)
Control M = 4; F = 2 71.2 ± 11.1 n/a
Medalist C M = 4; F = 2 74.5 ± 12.9 64.3 ± 11.3
Medalist +C M = 2; F = 4 77.2 ± 5.0 67.5 ± 8.5
Summarized in the table are clinical characteristics of patients with long-
standing T1D with severe (Medalist +C) or absent to mild (Medalist C)
diabetic complications as well as age-matched control or healthy sub-
jects that were used for the derivation of iPSCs. Clinical characteristics
of Medalists with absent to mild complications (Medalist C; % 1
complications: M1, M4, M10, M14, M17, and M22), Medalists with com-
plications (Medalist +C;R 2: M3, M6, M9, M11, M12, andM18), and age-
matched controls (Control: control 1, control 2, control 3, control 4,
control 5, and control 6), used for the derivation of fibroblasts from skin
biopsies. Human induced pluripotent stem cells (hiPSCs) reprogrammed
from these fibroblasts were used in the study. The number of patients in
each group is 6. Data are presented as mean ± SD. MedalistC: 0/6 with
CVD, 5/6 manifest DN Class 0-IIA, and 6/6 manifest no to mild NPDR.
Medalist +C: 6/6 with CVD, 5/6 exhibit DN Class IIB or IV, and 4/6 exhibit
PDR. CVD, cardiovascular disease; DN class, diabetic nephropathy
class; PDR, proliferative diabetic retinopathy; NPDR, non-proliferative
diabetic retinopathy; M, male; F, female; n/a, not applicable.neurons differentiated from Medalist +C iPSCs showed in-
creased susceptibility to DNA damage-induced apoptosis, as
compared to neurons derived from Medalist C or control
iPSCs, implying clinical significance. The reversal of DNA dam-
age upon knockdown of miR200 in fibroblasts as well as iPSCs
from Medalist +C patients points to a direct mechanistic role
for miR200. Collectively, our work highlights regulation of the
DNA damage checkpoint pathway by miR200 as a mechanism
underlying protection against diabetic complications. Targeting
of this pathway may lead to more effective interventions to
reduce the burden of T1D.
RESULTS
Impaired Growth, Reprogramming, and Self-Renewal in
Medalist +C Patient iPSCs
We report, for the first time to our knowledge, derivation of iPSCs
from patients with long-standing T1D with severe (Medalist +C)
or absent to mild (Medalist C) complications. Reprogramming
of skin fibroblasts from the T1D patients or age-matched con-
trols was performed by cre-excisable lentivirus (Figure S1A).
Table 1 summarizes the clinical characteristics of the fibroblast
donors. We derived six iPSC lines for each group including three
clones per line (a total of 54 lines). Interestingly, microscopic ex-
amination and flow cytometry analyses revealed larger cell size
(Figures 1A and 1B) and reduced growth potential in fibroblasts
from T1D patients (Figure 1C) compared to controls and
confirmed this in independent experiments (Figure S1B). We
also observed a striking impairment in the reprogramming effi-
ciency of fibroblasts from Medalist +C (Figure 1D), as assessed
by quantitative analyses of alkaline phosphatase positive col-
onies (Figure 1E). The growth potential of emerging iPSC col-
onies from Medalist +C was also impaired (Figure 1F). Despite
these phenotypes, the pluripotency of iPSCs from all clinical240 Cell Metabolism 22, 239–252, August 4, 2015 ª2015 Elsevier Incgroups was confirmed by expression of pluripotency markers
including OCT4, NANOG, SOX2, and SSEA4 (Figures S1C–
S1F), and staining for early (alkaline phosphatase, Figure S1G)
and late (Tra1-60, Figure S1H; Tra1-81, Figure S1I) pluripotent
cell-surface markers by live-cell imaging.
Impaired Cellular Differentiation in Medalist +C Patient
iPSCs
The differentiation potential of iPSCs was assessed by differenti-
ation at different time points over 8 weeks (early [0–2.5weeks], in-
termediate [2.5–5weeks], or late [5–8weeks] periods). Expression
of germ layer markers, using real-time qPCR analyses showed
impairment in the differentiation of Medalist +C iPSCs into the
endoderm lineageandacompleteblockadeofmesodermorecto-
derm lineages (Figure 2A). In addition, in contrast to the normal
differentiation of control iPSCs, Medalist C iPSCs showed de-
layed expression of mesodermal and ectodermal differentiation
markers and blunted expression of markers of endodermal
differentiation (Figure S2A). Consistently, in vitro assays showed
smaller and fewer embryoid bodies in Medalist +C (Figure 2B).
To investigate the physiological significance of these observa-
tions, we next assessed iPSC differentiation in vivo in non-obese
diabetic mice with severe combined immune deficiency (NOD-
SCID) injected with equal numbers of iPSCs from each
experimental group. Histological analyses (Figure S2B) and im-
munostaining for germ layer markers (Figures S2C–S2E) re-
vealed that iPSCs from all three groups gave rise to tissues of
all three germ layers. However, a significantly impaired cellular
differentiation in Medalist +C was identified both by a delay in
the timescale of differentiation (8 weeks for Medalist +C versus
4 weeks for controls or Medalist C, Figures 2C–2E) and the
presence of undifferentiated mesenchyme in >70% of the trans-
planted graft, evident upon histo-pathological investigation and
staining for themesenchymal stemcell marker, CD73 (Figure 2F).
Consistently, we detected a significant loss of ACINUS protein
expression (Figures S2F–S2H) and consequently serine-1004
phosphorylation-dependent activation, in Medalist +C cells (Fig-
ures S2F, S2G, and S2I). Failure to activate expression of
ACINUS, which is necessary for early differentiation of embry-
onic stem cells (ESCs) (Rigbolt et al., 2011; Van Hoof et al.,
2009) may, in part, underlie the impairment in differentiation
observed in Medalist +C patients. It is possible that exposure
of fibroblasts to prolonged periods of hyperglycemia in the
Medalist patients, and consequent hyperosmotic stress, would
have impacted their ability to reprogramming as well as the sub-
sequent potential for proliferation and/or differentiation (Ma-
donna et al., 2013) and requires further investigation.
Preserved DNA Damage Checkpoint Pathway Function
in Medalist –C Protects against DNA Damage-Induced
Cell Death
To investigate molecular defects underlying the complications in
Medalist +C and/or the protective factors preventing their
occurrence in Medalist C, we subjected donor fibroblasts to
microarray gene expression profiling. Comparative marker se-
lection revealed differential expression of genes associated
with diabetes between control and T1D patients (Table S1A; A,
B, and C), confirming the suitability of these cells for biomarker
profiling. Members of the DNA damage checkpoint family were.
Figure 1. Reduced Growth and Reprogramming Efficiency of Primary Fibroblasts from Medalist +C Type 1 Diabetes Patients
(A) Morphological characteristics of primary skin fibroblasts obtained from T1D Medalist C and +C and age-matched controls, Scale bar: 50 mm. Inset shows
magnified image.
(B) Flow cytometry analyses: quantitative size assessment of fibroblasts from the three clinical groups (Controls, Medalist C, and Medalist +C).
(C) Flow cytometry-based quantitation of BrdU incorporation, a surrogate for cell proliferation, in fibroblasts.
(D) Reprogramming of fibroblasts from the three groups, using lentiviral expression of OCT4, SOX2, KLF4, and c-MYC and assessment of number of emerging
iPSC clusters on day 14 of reprogramming. Scale bar: 100 mm.
(E) Quantitation of reprogramming efficiency across n = 6 reprogramming experiments.
(F) Dynamics of growth of Control, MedalistC, and Medalist +C iPSCs over time, 2, 4, 6, and 8 weeks after reprogramming with a polycistronic lentivirus. Scale
bar: 200 mm.
Data represent N = 6 independent subjects per clinical group in each experiment, repeated three times, represented as mean ± SD. # p value < 0.05;
*p value < 0.001. See also Figure S1.
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Figure 2. Impaired Differentiation Potential of iPSCs from Medalist +C Type 1 Diabetes Patients
(A) Assessment of markers of the three germ layers, by quantitative real-time qPCR analysis in iPSCs (Control, MedalistC, andMedalist +C) at various stages in
the spontaneous differentiation process.
(B) Embryoid body formation assay: in vitro differentiation of iPSCs. Scale bar: 100 mm.
(C) Teratoma assay: in vivo differentiation of iPSCs, post-injection into NOD-SCID mice.
(D) Quantitative assessment of teratoma size/volume resulting from the in vivo differentiation of iPSCs.
(E) Morphological imaging of differentiated tissue harvested fromNOD-SCIDmice after injection with iPSCs fromControl, MedalistC, andMedalist +C subjects.
(F) Fluorescence immunostaining analyses for CD73, amarker for undifferentiatedmesenchymal stem cells, in the differentiated tissue harvested fromNOD-SCID
mice after injection with iPSCs from Control, Medalist C, and Medalist +C subjects. Scale bar: 200 mm.
Data represent N = 4 independent subjects per clinical group and n = 3 clonal iPSC lines per subject in each experiment, repeated three times, represented as
mean ± SD. # p value < 0.05; *p value < 0.001. See also Figure S2.
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differentially expressed between Medalist C and +C (Figures
3A and 3B; Figure S3A; Table S1B and Table S2). Further ana-
lyses revealed overexpression of genes related to NF-kB and
other inflammatory pathways in Medalist +C fibroblasts (Fig-
ure 3C). Western analysis showed a protein level impairment of
all DNA damage checkpoint proteins, including ATM (Figure 3D),
ATR (Figure 3E), and DNA-PK (Figure 3F) regulated inMedalist +-
C fibroblasts compared to both Medalist C and controls.
Consistently, Medalist +C cells showed an increased expression
of phosho-H2AX and phospho-Ser15-p53 (Figure 3G), suggest-
ing a higher burden of DNA damage due to an impaired repair
process. These observations were further supported by a posi-
tive enrichment profile of genes in the ATR/BRCA pathway (Fig-
ure S3B), UV response cluster (Figure S3C), and proteasome
complex (Figure S3D) in fibroblasts from Medalist C. To inves-
tigate the abundance of DNA damage checkpoint proteins in
iPSCs, we next performed MS-based quantitative proteomics
(Figures S4A and S4B) and confirmed the impairment of the
DNA damage checkpoint machinery in Medalist +C iPSCs (Fig-
ure 3H; Table S3 and Table S4; see accessory information on
Figures 1A–1D in Supplemental Information). High enrichment
scores of ATM/ATR/BRCA-DNA repair proteins (Figure S4C),
UV response pathway (Figure S4D), and proteasomal DNA repair
components (Figure S4E) in Medalist C iPSCs supported our
initial observations. Interestingly, expression of most DNA dam-
age checkpoint proteins was highest in Medalist C patients
(Figure S4F). We confirmed these results by western immunoblot
analyses in iPSCs showing significantly reduced expression of
key proteins in the DNA damage checkpoint pathway, including
but not limited to pATM, Mre11, pBrca1, Rad52, and Ku80 in
Medalist +C iPSCs compared to both Medalist C and control
iPSCs (Figure 3I). Furthermore, phospho-proteomics analyses
revealed a significant impairment in the activation of MDC1 in
Medalist +C iPSCs (see accessory information on Figures 1E–
1G in Supplemental Information), a key factor that initiates the
DNA damage checkpoint by binding pH2AX in response to
cellular DNA damage (Spycher et al., 2008; Stucki et al., 2005)
while tightly coordinating the repair with cell cycle and mitosis
(Branzei and Foiani, 2008; Dephoure et al., 2008; Goldberg
et al., 2003; Stewart et al., 2003). Of clinical relevance, integrated
pathway analyses revealed a significant association of proteins
differentially expressed between Medalist C and +C cells to
cardiovascular, neurological, ophthalmic, and renal diabetic
complications, secondary to defects in DNA damage checkpoint
pathway and recombination, chromosome assembly, and
cellular response to stress (Table S5).
Taken together, these data suggest a preserved DNA damage
checkpoint pathway is essential for protection from diabetic
complications in the Medalist C subgroup.
Suppressed miR200 in Medalist –C Preserves DNA
Damage Checkpoint Pathway and Protects against
Apoptosis
In silico analyses of genomics and proteomics data demon-
strated an enrichment of direct miR200 targets within the DNA
damage checkpoint pathway repair genes/proteins differentially
expressed between MedalistC and +C (e.g., ATM, ATR, Rad1,
17, 50, Mre11, Brca1) (depicted by red boxes in Figure 4A, Table
S6; A and B, and Figure S5A). Other proteins that were non-tar-Celgets of miR200, such as p53 and Cyclin B, were expressed at
comparable levels among the three groups. To directly evaluate
this pathway, we used two cell types known to be affected in
T1D, neurons and endothelial cells. Indeed, overexpression of
miR200 in neuronal cells resulted in a loss of ATM (a key compo-
nent of the DNA damage checkpoint pathway), with concomitant
increases in cleaved caspase-3 and nuclear pH2AX (Figures 4B
and 4C; Figures S5B–S5D). These findings were corroborated in
primary human endothelial cells, a target cell involved in diabetic
complications (Figures 4D and 4E; Figure S5E). Previous reports
indicate that cells exposed to stress undergo apoptosis due to
nuclear loss of DNA repair proteins, particularly Ku isoforms
(Song et al., 2003), downregulated in the Medalist +C (Figure 3I),
presumably due to upregulation of miR200. Supporting this
finding, we identified the miR200 target sequence in several
components of the DNA damage checkpoint pathway (Fig-
ure S5A), a majority of which were downregulated in Medalist +C
cells (Figures 3D–3F and 3I).
Restoration of ATM function in the presence of elevated
miR200 reduced DNA damage to control levels, confirming that
miR200-mediated increase in DNA damage/cellular apoptosis
occurs, in part, through its actions on ATM protein (Figures 4C
and4E, lower panels). Our findings in both neuronal and endothe-
lial cells provide compelling evidence for broad clinical relevance
of these observations. Notably, directed differentiation of these
patient-derived iPSCs into the neuronal lineage revealed an in-
crease in DNA damage, observed by a 6-fold upregulation of
nuclear pH2AX staining, in Medalist +C-derived neurons, pre-
sumably due to an impaired DNA damage checkpoint pathway
response (Figures 5A and 5B; Figures S6A and S6B). Subjecting
these differentiated neurons to overexpression of miR200 further
increased DNA damage while reducing cellular viability (as
observed by Trypan blue staining), with more dramatic effects in
Medalist +C compared to Medalist C or controls (Figures 5C
and 5D). Of likely clinical relevance, elevated levels of miR200
were observed in iPSCs (Figure 6A) and sera from Medalist +C
(Figure 6B). The ability to detect miR200 in blood is consistent
with previous reports that miRNAs are present in the circulation
(reviewed in Kato et al., 2013; Epstein, 2014). Indeed, circulating
miRNAs have been suggested to originate from several sources
relevant to our studies including inflammatory foci (Kong et al.,
2010), endothelial cells (Chamorro-Jorganes et al., 2013), or
mononuclear cells and platelets (Hunter et al., 2008).
Enhanced presence of miR200 presumably reflects its epige-
netic de-repression by potential chromatin modifiers differen-
tially regulated between Medalist C and +C in proteomics
analyses (Table S3 and Table S4), as suggested by previous re-
ports (Vrba et al., 2010). Consistently, we observed reduced
expression of DNA damage checkpoint protein(s) such as ATM
and increased expression of pH2AX and cleaved caspase-3 in
primary aortic tissue obtained from Medalist +C, compared to
both Medalist C and controls (Figure 6C).
miR200 Knockdown Restores Expression of DNA
Damage Checkpoint Proteins in Both Medalist +C
Fibroblasts and Medalist +C Human iPSCs
To evaluate whether miR200 is directly involved in reprogram-
ming and in modulating the expression of proteins in the DNA
damage checkpoint pathway, we first successfully knockedl Metabolism 22, 239–252, August 4, 2015 ª2015 Elsevier Inc. 243
Figure 3. Impairment of DNA Double Strand Break Repair in Fibroblasts and iPSCs From Medalist +C Type 1 Diabetes Patients
(A) Genematrix representing DNA damage repair as one of the most differentially expressed functional gene clusters in microarray analysis of fibroblasts from the
three clinical groups (Control, Medalist C, and Medalist +C) (N = 2; n = 4).
(B) Heatmaps showing downregulation (blue) of genes involved in DNA repair, cell cycle, metabolism, etc. in Medalist +C fibroblasts compared to Medalist C
and controls.
(C) Heatmaps showing upregulation (red) of genes involved in inflammation andNF-kBpathway inMedalist +C fibroblasts compared toMedalistCand controls.
(D) Western immunoblot analysis in fibroblasts highlighting impairment in DNA damage checkpoint proteins involving ATM.
(E) DNA damage checkpoint proteins involving ATR.
(F) DNA damage checkpoint proteins involving DNA-PK.
(legend continued on next page)
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down (KD) miR200 (A, B, and C together) in Medalist +C iPSCs
(Figure 7A) and in Medalist +C fibroblasts (Figure 7B). Examina-
tion of reprogramming efficiency of Medalist +C fibroblasts
treated with miR200 siRNA revealed no significant differences
compared with Medalist +C fibroblasts treated with scrambled
siRNA (Figure 7C). However, western analysis showed rescue
of DNA damage checkpoint protein expression as evidenced
by elevated levels of ATM and ATR in miR200 KD Medalist +C
fibroblasts (Figure 7D). Rescue of this pathway was also sup-
ported by reduced presence of phospho-H2AX and cleaved
caspase-3 in Medalist +C fibroblasts with a KD of miR200, sug-
gesting a direct role for miR200 in the regulation of DNA damage
(Figure 7E). Furthermore, the rescue effects were also detected
in Medalist +C iPSCs with a KD of miR200, as shown by reduced
immunostaining for phospho-H2AX protein in these cells, as
compared to scrambled siRNA treated Medalist +C hiPSCs
(Figures 7F and 7G). Quantitative-PCR analysis showed a
similar level of hTERT mRNA expression between the different
experimental groups, indicating that telomere length is not
likely to be altered in the age-matched control, Medalist C
and Medalist +C fibroblasts (Figure 7H). Together, these data
support a direct role for miR200 in regulating the DNA
damage checkpoint pathway machinery by modulating the
expression of DNA damage checkpoint proteins. Thus, in a sub-
set of patients with T1D, such as the MedalistC, the DNA dam-
age checkpoint pathway is preserved secondary to suppressed
miR200 expression in order to prevent apoptosis and to protect
against the development of diabetic complications.
DISCUSSION
Lack of Suitable Cellular or Animal Models Mimicking
Human Diabetic Complications
Micro- and macro-vascular diabetic complications are a major
cause of morbidity and mortality, highlighting the urgent need
for therapeutic intervention (Georgescu, 2011; Mabed and Sha-
hin, 2012). Although several molecular defects have been impli-
cated, and modulators of vascular endothelial growth factor
(VEGF), advanced glycation end products (AGE), and its recep-
tor (RAGE) have reached human clinical trials (Brownlee et al.,
1988; Harja et al., 2008; Nishikawa et al., 2000; Park et al.,
1998), therapeutic success has been limited, due in part to the
lack of cellular/animal models that fully mimic the human disease
phenotype (Calcutt et al., 2009; Onat et al., 2011). iPSCs from our
unique medalist group of patients with longstanding T1D with
and without complications (Keenan et al., 2007, 2010) provide
a excellent opportunity for potential cell-based therapy and
cellular disease modeling, while retaining the genetic make-up
of the patients. Unbiased microarray and proteomic profiling of(G) Western immunoblot analysis in fibroblasts, highlighting increased express
compared to Medalist C or controls.
(H) MS-based quantitative proteomics analysis shows DNA damage repair prote
iPSCs (N = 4; n = 2).
(I) Western immunoblot analysis in iPSCs from the three clinical groups, highlightin
Medalist C or controls.
Data represent N = 4 independent subjects per clinical group and n = 3 clonal iPSC
at least three times. # p value < 0.05; *p value < 0.001. For Figures 3D–3G, addition
S4 and accessory information on Figure 1 in Supplemental Information.
Celprimary fibroblasts and iPSCs, respectively, revealed impair-
ment of key regulators of metabolism, energy homeostasis and
mitochondrial function (electron transport chain) in T1DMedalist
cells, irrespective of complication status. These data suggest the
cells manifest effects secondary to the diabetes in the patients
and confirm the usefulness of the iPSCs in modeling the disease
(Table S1 A, B, and C). The retention of a majority of the differen-
tially regulated genes or proteins in patient fibroblasts and iPSCs
indicates conservation of the genetic make-up of the patients
and signifies their suitability for disease modeling.
Preserved DNA Damage Checkpoint Pathway Function
in Medalist –C, Secondary to Suppressed miR200
Expression, Protects against Diabetic Complications
An unbiased systems biology approach involving genomics and
proteomics analyses to compare Medalist C and Medalist +C
revealed alteration(s) in the DNA damage checkpoint path-
way machinery. These ‘‘protective factors’’ were significantly
elevated in Medalist C. Further interrogation revealed an
elevated basal expression of miR200 in fibroblasts (miR200
transcript was undetectable in fibroblasts from controls and
Medalist C) and iPSCs derived from Medalist +C, compared
to Medalist C and controls. Strikingly, miR200 KD restored
DNA damage checkpoint protein expression in both fibroblasts
and iPSCs derived from Medalist +C patients. Indeed, consis-
tent with our findings, previous studies have reported silencing
of miR200 expression in fibroblasts under normal conditions
due to increased promoter methylation (Vrba et al., 2010).
Future studies aimed at comparing gene/protein expression in
fibroblasts and iPSCs from these clinical groups may aid in
identifying epigenetic regulators that underlie the methylation-
based silencing of miR200 in fibroblasts while being de-
repressed in iPSCs and could be therapeutically important in
the context of targeting miR200-regulated pathways (Liu et al.,
2013; Price and D’Andrea, 2013; Xu et al., 2012b; Zhou et al.,
2011). Furthermore, we found a significant impairment in the
activation of MDC1 (serine-793), a protein suggested to be
key for the recruitment of DNA damage checkpoint pathway
machinery to the damaged site to regulate DNA damage check-
point pathway function and for insuring normal cell cycle
progression (Bennetzen et al., 2010; Branzei and Foiani, 2008;
Dephoure et al., 2008; Goldberg et al., 2003; Stewart et al.,
2003; Lee and Paull, 2005; Falck et al., 2005). We also observed
that topoisomerases, PARPs, and proteasomal components
that are implicated in early steps of DNA damage checkpoint
pathway damage recognition and repair showed reduced
expression in Medalist +C (Lin et al., 2009; Xu et al., 2012a; Fur-
uta et al., 2003). Elevated expression of cleaved caspase-3,
concomitant with the DNA damage checkpoint pathwayion of pH2AX and pSer15-p53, surrogate for DNA damage, in Medalist +C
ins to be most differentially expressed between Medalist C and Medalist +C
g impairment of DNA damage checkpoint proteins in Medalist +C compared to
lines per subject in each experiment unless indicated otherwise and repeated
al fibroblast lines were used for MedalistC samples. See also Figures S3 and
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Figure 4. Impaired Expression of DNA Damage Checkpoint Pathway Proteins Secondary to miR200 Overexpression Leads to Apoptosis in
Medalist +C Type 1 Diabetes Patients
(A) Schematic of DNA damage checkpoint pathway machinery, adapted from Cell Signaling, Inc., showing genes predicted to be miR200 targets in red box.
(B) Western immunoblot analyses in primary human neurons subjected to miR200 overexpression (48 hr) followed by 24-hr treatment with either vehicle (5 mM
glucose) or high glucose (25 mM glucose).
(C) Immunostaining analyses of pH2AX in primary human neurons subjected to miR200 overexpression (48 hr) followed by rescue of the DNA damage phenotype
by re-expression of ATM and 24-hr treatment with either vehicle (5 mM glucose) or high glucose (25 mM glucose) (pH2AX, green; DAPI, blue). Scale bar: 50 mm.
(legend continued on next page)
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Figure 5. Increased DNA Damage Wors-
ened by miR200 Overexpression in Neurons
Differentiated from Medalist +C Type 1 Dia-
betes Patients
(A) Immunostaining analyses of pH2AX (marker for
DNA damage) and Neu-N (marker for neurons) in
neuronal-like cells obtained from directed differ-
entiation of human iPSCs from the three clinical
groups including Control 2 and Control 3 as
healthy controls, M4 andM14 asMedalists without
neuropathy, and M6 and M9 as Medalists with
neuropathy (pH2AX, green; Neu-N, red; DAPI,
blue). Scale bar: 50 mm.
(B) Quantitation of nuclear H2Ax foci across mul-
tiple experiments described in (A).
(C) Immunostaining analyses of pH2AX (marker
for DNA damage) and Neu-N (marker for neurons)
in neuronal-like cells obtained from directed dif-
ferentiation of human iPSCs from the three clin-
ical groups post-miR200 overexpression (48 hr)
(pH2AX, green; Neu-N, red; DAPI, blue).
(D) Quantitation of nuclear H2Ax foci across
multiple experiments described in (A). Scale
bar: 50 mm.
See also Figure S6. All experiments were
repeated three times, represented as mean ± SD.
*p value < 0.001.impairment, was observed in multiple target cells (neurons
and endothelial cells), with elevation in the presence of high
glucose, modeling the manifestations of diabetic complica-
tions in Medalist +C and protection in Medalist C (due to
elevated DNA damage checkpoint pathway machinery,
despite hyperglycemia) or controls (due to optimal DNA dam-
age checkpoint pathway function and normoglycemia).
Corroboration of these novel findings in two cell types
affected in T1D (neurons and endothelial cells) and the
increased susceptibility of neurons differentiated from
Medalist +C iPSCs to genotoxic stress (exposure to high
glucose, UV irradiation, or Etoposide), compared to Medalist
C or controls, underscore the clinical relevance of these ob-
servations. Further, the confirmation of our findings in both
in vitro differentiated cells (e.g., neurons derived from differen-
tiation of patient iPSCs) as well as tissues involved in diabetic
complications (e.g., aortic tissue obtained from the patients),
and the ability to reverse expression of DNA damage check-
point pathway proteins upon KD of miR200 in fibroblasts
and iPSCs, highlights the significance of this pathway for po-
tential therapeutic targeting. Whether the circulating miR200 in(D) Western immunoblot analyses in primary human endothelial cells subjected to miR200 overexpression (48
(5 mM glucose) or high glucose (25 mM glucose).
(E) Immunostaining analyses of pH2AX in primary human endothelial cells subjected to miR200 overexpress
phenotype by re-expression of ATM and 24-hr treatment with either vehicle (5 mM glucose) or high glucose (
bar: 50 mm.
All experiments were repeated three times, represented as mean ± SD. *p value < 0.001. See also Figure S5
Cell Metabolism 22, 239–25our studies originates from damaged
endothelial cells, which are known to
exist in diabetic patients and/or other
cell types, and could serve as a poten-tial biomarker for diabetic complications (Kato et al., 2013)
warrants careful investigation.
Impaired Cellular Differentiation Potential in
Medalist +C Underscores Manifestation of Diabetic
Complications
Under normal conditions, humans have an inherent capacity for
differentiation and self-renewal to make up for the loss of func-
tionally mature cells in a tissue, secondary to normal senescence
or stress-induced apoptosis, from a pool of progenitor cells that
maintain the levels of functional lineage committed and/or
mature cells required for normal function (Nakada et al., 2011;
Ruiz et al., 2011). However, in disease states, when this endog-
enousmechanism fails, complications arise requiring pharmaco-
logical intervention, cell-replacement therapy (b cells), or organ
transplantation (kidney, heart etc.). Consistently, we observed
a severe impairment in the differentiation potential of iPSCs
derived from Medalist +C patients, both in vitro and in vivo.
Further investigation revealed that Medalist +C cells have
reduced levels and activation of ACINUS protein, which is impli-
cated in the early differentiation and lineage commitment inhr) followed by 24-hr treatment with either vehicle
ion (48 hr) followed by rescue of the DNA damage
25 mM glucose) (pH2AX, green, DAPI, blue). Scale
.
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Figure 6. Increased miR200 Expression in
Medalist +C Patients Impairs DNA Damage
Checkpoint Pathway Protein Function,
Increasing Susceptibility to Cell Death and
Apoptosis
(A and B) Quantitative real-time qPCR analysis in
(A) iPSCs (controls: N = 4, Medalist C: N = 4, and
Medalist +C: N = 4) and (B) human sera (controls:
N = 6, Medalist C: N = 2, and Medalist +C: N = 6)
to assess relative circulating levels of miR200.
(C) Protein expression analyses in aorta obtained
from human subjects from the three groups.
All experiments were repeated three times, rep-
resented as mean ± SD. *p value < 0.001.embryonic stem cells, through phosphorylation at serine-1004.
In the Medalist +C group, our findings reveal increased inflam-
mation due to macrophage infiltration and increased apoptosis
due to elevated DNA damage, resulting in cellular loss, which
is not compensated by differentiation of progenitor cells, pre-
sumably due to impairment in ACINUS protein function.
Collectively, our findings underscore the relevance of miR200
in regulating the DNA damage checkpoint pathway and cellular
capacity of self-renewal and differentiation while its impairment
leads to cellular inflammation and apoptosis. We therefore pro-
pose the design of new interventions targetingmiR200 to protect
from the onset and progression of diabetes-associated compli-
cations in humans.EXPERIMENTAL PROCEDURES
Primary Human Fibroblast Derivation and Culture
All studies involving human material were approved by the Institutional Review
Board, Joslin Diabetes Center and were in accordance with NIH guidelines.
Skin biopsies were obtained from human subjects and sustained in DMEM
(10-027, Cellgro Inc.) supplemented with 10% heat-inactivated fetal bovine
serum, 1% sodium pyruvate (Life Technologies), and 1% penicillin-strepto-
mycin (Mediatech Inc.), over a period of 4 weeks, in a 6-well plate, with media
supplementation every other day. Subsequently, as fibroblasts emerged from
the primary explant, a brief trypsinization (0.25% Trypsin) was used to sepa-
rate and further expand the cells in a 10-cm2 plate. For ligand stimulation
studies, primary human fibroblasts were cultured in DMEM supplemented
with 1 mM glucose followed by 48-hr treatment with either Vehicle (5 mM
glucose) or 25 mM glucose.
Human Studies in the Medalist Patients
Individuals who had documented 50 or more years of insulin use for T1D were
invited to participate in a baseline visit. Informed consent was obtained from all
subjects prior to participation in the study and after approval by the Joslin Dia-
betes Center Committee on Human Studies.248 Cell Metabolism 22, 239–252, August 4, 2015 ª2015 Elsevier Inc.Assessment of Complications Status
Nephropathy, retinopathy, and neuropathy status
have been defined previously (Keenan et al.,
2010). Briefly, diabetic nephropathy was defined
by an estimated glomerular filtration rate (CKD-
eGFR) of <45 ml/min/1.73 m2. A dilated eye exam-
ination was performed, and retinopathy status was
graded using guidelines from the Early Treatment
Diabetic Retinopathy Study (ETDRS). Proliferative
diabetic retinopathy (PDR) was defined as an
ETDRSR60. The Michigan Neuropathy Screening
Instrument was used to assess neuropathy; scores
>2 were considered positive. Cardiovascular dis-ease status was based on self-reported history of coronary artery disease,
angina, heart attack, prior cardiac or leg angioplasty, or bypass graft surgery.
Coronary artery disease required assessment by a clinician for the presence of
angina, heart attack, history of cardiac angioplasty, or bypass graft surgery.
Generation of Human iPSCs by Lentiviral Reprogramming
Human skin fibroblasts were transduced with hSTEMMCA Cre-Excisable
Polycitronic lentivirus (EMD Millipore) expressing OCT4, SOX2, KLF4, and
cMYC (Sommer et al., 2009), driven by a single promoter, in the presence of
5 mg/ml Polybrene (EMD Millipore). Details are in Supplemental Experimental
Procedures.
Embryoid Body Formation Assay
hiPSC colonies were manually scored under a microscope. Cell clumps were
briefly spun at 200 g for 2 min at room temperature and resuspended into 4 ml
embryoid body (EB) media (hiPSC growth media with 2% FBS, without bFGF
supplementation) and seeded onto 12-well untreated ultra-low attachment
plates (3737, Corning). Plates were shaken every 12–16 hr to prevent attach-
ment of cells onto the plate surface. Culture media was replaced every
3 days until the EB formation could be observed in approximately 10–14 days.
Animal Housing and In Vivo Differentiation Assays
All animal study protocols were approved by the Institutional Animal Care and
Use Committee (IACUC), Joslin Diabetes Center and were in accordance with
NIH guidelines. NOD SCID male mice (NOD.CB17-Prkdcscid/NCrCrl, Charles
River) were obtained when 4 weeks old, housed in pathogen-free facilities,
andmaintained on a standard rodent chowdiet (2020X, Harlan TeklandGlobal)
with a 12 hr light/12 hr dark cycle at the Animal Care Facilities of Joslin Dia-
betes Center. Mice were anesthetized with Avertin (240 mg/kg intraperitone-
ally) before intramuscular injection of human iPSCs (approximately 2 3 106
cells harvested as cell clumps, in a 5:1 mixture with Matrigel [BD Biosciences]
and final volume of 150 ml) with a 21G needle. Animals weremonitored over the
next 4–8weekswhile the teratomas started to emerge/grow, and the sizemea-
surements were recorded every week using Vernier calipers.
Lentiviral Overexpression of miR200
For miR200 overexpression, genomic fragments encoding cluster-A
(miR200b/200a/429) or cluster-B (miR200c/141) cloned into pLenti 4.1Ex
Figure 7. Rescue of DNA Damage Checkpoint Proteins by miR200 Knockdown in Human Medalist +C Fibroblasts and iPSCs
(A and B) Quantitative real-time qPCR analysis to assess combined knockdown (KD) of miR200A, miR200B, and miR200C in (A) iPSCs of Medalist +C patients
(N = 6) or (B) Medalist +C fibroblasts (M6, M9, and M12; N = 3).
(C) Quantitation of reprogramming efficiency of human Medalist +C fibroblasts (M6, M9, M12) treated with scrambled siRNA or miR200 siRNA (N = 3).
(D) Immunoblot analysis highlighting the restoration of ATM/ATR proteins in Medalist +C fibroblasts (M6, M9, M12) treated with miR200 siRNA compared to
scrambled siRNA (N = 3).
(E) Immunoblot analysis showed decreased expression of pH2AX/cleaved caspase-3 in Medalist +C fibroblasts treated with miR200 siRNA (N = 3).
(F) Immunostaining analysis of pH2AX in miR200 siRNA-treated Medalist +C human iPSCs as compared with scrambled siRNA-treated iPSCs. pH2AX, green;
DAPI, blue. Scale bar: 50 mm.
(legend continued on next page)
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backbone vector were obtained from Addgene plasmid repository, plasmids
35533 and 35534, respectively. Lentivirus production involved five plasmid
co-transfection of 293FT cells, involving the lentiviral expression cassette con-
taining the gene of interest (GOI), tat, rev, gag/pol, and vsv-g plasmids (in the
ratio 20:1:1:1:2) using calcium phosphate transfection method (Clontech Lab-
oratories Inc.) and LentiX (Clontech Laboratories Inc.)-mediated concentration
of viral particles and titering before storage at 80C in aliquots for long-term
use. All virus infections used 5 mg/ml Polybrene reagent (EMD Millipore).
miR200 Expression Analyses in Human Sera, Fibroblasts, and iPSCs
For miR200 expression analyses, total RNA was extracted using either fibro-
blasts, iPSCs, or serum samples obtained from three clinical groups (Control,
Medalist C, and Medalist +C) using standard TRIzol-based RNA extraction
protocols in the presence of RNase inhibitors (Life Technologies) and DNase
treatment (QIAGEN). RNA measurements used ND-1000 spectrophotometer
V3.5 (NanoDrop Technologies, Inc.). Samples with a 260/280 optical densi-
tometry ratios of 2 were used for further analyses that included cDNA conver-
sion using miRCURY LNA Universal RT microRNA PCR cDNA synthesis kit
(Exiqon). A total of 5 ng/ml cDNA was thereafter subjected to a nested quanti-
tative real-time PCR analysis using primers for miR200a, miR200b, and
miR200c in equimolar ratios (500 nM each) in a standard 10-ml reaction volume
and 384-well format, SYBR Green-based assay (Life Technologies, Roche).
Primer sequences can be found in Table S7.
miR200 Knockdown in Human Fibroblasts and hiPSCs
Human fibroblasts from Medalist +C patients were plated as a single-cell sus-
pension into 6-well plates and subjected to siRNA-mediated KD of miR200
using 50 nM siRNA inhibitors from Exiqon for 48 hr. Thereafter, cells were
collected and lysed for western blot analysis described in Experimental Proce-
dures. Similarly, iPSCs from Medalist +C patients were plated as single-cell
suspension into 24-well plates and subjected to siRNA-mediated KD of
miR200 using 20 nM siRNA inhibitors from Exiqon for 72 hr. Thereafter, cells
were fixed and subjected to immunostaining analyses, described in Experi-
mental Procedures. In both cases, scrambled siRNA was used as a control.
Whole-Genome Microarray Gene Expression Profiling
Primary human fibroblasts from healthy controls, T1D Medalist C, and T1D
Medalist +C (N = 2, n = 4), cultured as described previously, were subjected
to RNA extraction using RNeasy Plus kit (QIAGEN) following manufacturer
guidelines. In the present study, ‘‘N’’ represents biological replicates and ‘‘n’’
denotes clonal (in case of iPSCs) or technical replicates. RNA integrity and
quality assessment was performed using Agilent 2100 Bioanalyzer (Agilent
Technologies) at the Microarray and Genomics core facility at Children’s Hos-
pital, Boston. RNA amplification utilized Ambion Illumina Amplification Kit. A
total of 850 ng of amplified RNA was used for subsequent labeling, adaptor
ligation, and hybridization onto HumanHT-12 v4.0 Expression BeadChip (Illu-
mina), using manufacturer protocols and recommendations. The BeadChip
that consists of more than 47,000 probes can run 12 samples simultaneously
and has its content derived fromNCBI RefSeq Release 38 (November 7, 2009),
as well as legacy UniGene content. Beadchips were scanned using the
Illumina BeadArray Reader, and expression data were extracted using the
BeadStudio software, using background subtraction. Rescaling was used to
eliminate negative values, if and wherever applicable, followed by quantile
normalization.
LC-MS/MS Proteomics Analyses
Peptidemixtures were analyzed on a high-resolution, reversed-phase capillary
LC system coupled with a Thermo Fisher Scientific LTQ-Orbitrap Velos MS.
Due to the limitation of four-plex iTRAQ labeling reagents, samples were pro-
cessed in two batches (Experiment 1 had a total of 12 samples, N = 2, n = 2 for(G) Quantitative analyses of immunostaining of pH2AX in human iPSCs (N = 6) deriv
miR200 (72 hr).
(H) Quantitative real-time PCR analysis showing the expression of hTERT gene in c
M12) (N = 2).
All data are presented as mean ± SD. *p value < 0.001.
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each clinical group). Sample preparation and other details are in Supplemental
Experimental Procedures.
Proteomics Data Analyses
iTRAQ-labeled peptides were identified based on tandem MS/MS spectra
using the Sequest search algorithm against a human protein database
(UniprotKB, released 2012-04), and the abundance information across four-
plex samples was extracted from the report ion intensities within a given
spectra. All peptides were identified with < 0.1% False Discovery Rate by us-
ing a MS-Generating Function Score (MS-GF) < 1E-10 and a decoy database
searching strategy. The reporter ion intensities for each peptide were summed
for all identified spectra for each channel in each biological condition. Relative
abundances at peptide level were rolled up to the protein level using the soft-
ware tool DAnTE (Polpitiya et al., 2008) with the abundances being log2 trans-
formed and normalized by the central tendency approach.
Primary Human Neuronal and Endothelial Cell Culture
Primary human neurons obtained from ScienCell Research Laboratories
(Cat# 1520) were sustained in growth factor (Cat# 1562) supplemented media
(Cat# 1521) with 10% heat-inactivated fetal bovine serum, as per vendor
recommendations. Primary human endothelial cells were obtained from
Lonza (Cat# CC-7030 AMP) and maintained in basal growth media supple-
mented with growth factors (CC-3202 KT). Both cell types maintained normal
growth and phenotypic characteristics and were used for ten passages. For
ligand stimulation studies, cells were cultured in growth media with 1 mM
glucose followed by 48-hr treatment with either Vehicle (5 mM glucose) or
25 mM glucose.
Directed Differentiation of Human iPSCs into Neuronal Lineage
Human iPSCs were cultured under sterile conditions in mTeSR media (Stem-
Cell Technologies). Standard tissue culture plates were coated with BD Matri-
gel hESC-qualified Matrix (BD Biosciences) for 1 hr at room temperature. For
passaging and/or directed differentiation, iPSCs were dissociated using Colla-
genase (StemCell Technologies Inc.), washed with Phosphate-Buffered Saline
(pH 7.4) (GIBCO), and replated using mTeSR supplemented with 3 mg/ml
Y-27632 Rho Kinase inhibitor (Cat# CD0141; Chemdea) and/or frozen using
mFreSR media (StemCell Technologies). rtTA3 and Ngn2 lentiviral constructs
for inducing neuronal differentiation of human iPSCs were cloned as described
in Supplemental Experimental Procedures and viruses were prepared similar
to protocols described in the earlier section for miR200 virus generation. Equal
number of manually scored iPSCs from all three clinical groups were then in-
fected with rtTA3 and Ngn2 and induced with 0.5 mg/ml doxycycline (Sigma).
Two to four days post-induction, cells were selected with puromycin and hy-
gromycin. Cells with neuronal-like projections that stained positive to neuronal
markers such as Neu-N appeared within a week and were further assessed for
morphological, phenotypic differences between clinical groups.
Human Tissue Extraction and Protein Expression Analyses in Aortic
Bio-Specimens
Human aortic tissue biopsies were obtained from patients with long-standing
T1D, snap frozen in liquid nitrogen, and stored at80C for long-term use. For
protein analyses, the tissue was suspended in tissue protein extraction re-
agent, T-Per, from Thermo Scientific, in the presence of protease and phos-
phatase inhibitor cocktail from the same manufacturer. The tissue specimen
was thereafter lysed through mechanical shearing using a tissue homogenizer
from Omni International and incubated at 4C for 30 min with vortexing at
maximum speed for 30 s after every 10 min. Protein estimation and western
analyses were performed as described in Supplemental Experimental
Procedures.ed fromMedalist +C patients and subjected to siRNA-mediated knockdown of
ontrol (cntrl1, cntrl2), MedalistC (M4, M10), andMedalist +C fibroblasts (M6,
.
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